Neuroinflammation, immune system and Alzheimer disease: searching for the missing link

Abstract

Due to an increasingly aging population, Alzheimer disease (AD) represents a crucial issue for the healthcare system because of its widespread prevalence and the burden of its care needs. Several hypotheses on AD pathogenesis have been proposed and current therapeutical strategies have shown limited effectiveness. In the last decade, more evidence has supported a role for neuroinflammation and immune system dysregulation in AD. It remains unclear whether astrocytes, microglia and immune cells influence disease onset, progression or both. Amyloid-β peptides that aggregate extracellularly in the typical neuritic plaques generate a constant inflammatory environment. This causes a prolonged activation of microglial and astroglial cells that potentiate neuronal damage and provoke the alteration of the blood brain barrier (BBB), damaging the permeability of blood vessels. Recent data support the role of the BBB as a link between neuroinflammation, the immune system and AD. Hence, a thorough investigation of the neuroinflammatory and immune system pathways that impact neurodegeneration and novel exciting findings such as microglia-derived microvesicles, inflammasomes and signalosomes will ultimately enhance our understanding of the pathological process. Eventually, we should proceed with caution in defining a causal or consequential role of neuroinflammation in AD, but rather focus on identifying its exact pathological contribution.

The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma

“…In AD patients, the production of MVs is very high, reflecting microgliosis. These extracellular vesicles can be isolated form cerebrospinal fluid (Guerriero et al, 2016). …”

Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested

“…Low static magnetic field has been studied in animal models, and transcranial magnetic stimulation with a high magnetic field has been investigated as a noninvasive therapeutic tool to treat neurological and psychiatric diseases [13]. The implication of various altered processes in AD, such as mitochondrial dysfunction [14] or inflammatory processes [15], support transcranial stimulation. Alternative hypotheses point the importance of brain-gut axis in neurodegenerative diseases [16] and suggest the interest of an abdominal stimulation.…”

Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer’s Disease Therapeutic Target

“…Chronic neuroinflammation and neurodegeneration play crucial roles in the pathophysiology of AD [7-12]. Microglia are the key players in neuroinflammation [13-16].…”